ArticleCureus2025
One-Stage Hepatectomy for Bilateral Liver Metastasis After Portal Embolization: Tumor Behavior of the Non-embolized Contralateral Lobe.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Two-stage hepatectomy is a well-known strategy for bilobar liver metastases, "cleaning" the future liver remnant (FLR) in the first stage, using portal vein embolization (PVE), and performing a major hepatectomy in the second stage. We used an alternative approach, performing PVE, to continue chemotherapy and perform liver resection. We describe our experience emphasizing liver hypertrophy and the tumor behavior of the contralateral liver metastasis. Methods Non-concurrent cohort study. Patients who underwent PVE before liver resection for bilobar metastases were included. Pre-PVE variables, post-PVE volumetry, variation of metastasis diameter in the FLR, perioperative variables, and overall survival were evaluated. Results Fifteen patients were included. Neoadjuvant chemotherapy was given in 14 patients (93.3%). Median FLR pre- and post-PVE were 20.4% and 31.5%. The median degree of hypertrophy was 46.2%. Median kinetic growth rate was 1.9% per week. The metastasis diameter decreased or was maintained in 11 patients (73.3%) after PVE. Twelve (80%) underwent R0 resection. Major postoperative morbidity occurred in two patients (13.3%); no early mortality was reported. Conclusions One-stage hepatectomy after PVE effectively achieves an adequate FLR, with contralateral tumor growth absent in most cases. This allows the continuation of chemotherapy during the hypertrophy period and achieves R0 resection of bilobar metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.